Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SciSparc Ltd.
Seeing strong sales with legacy Allergan’s Vraylar, AbbVie teams with Gedeon Richter on novel dopamine receptor modulators. AB Studio, CR Biopharma partner on COVID-19 neutralizing antibody.
Indoco has seen growth in Q3 FY22 based on the performance of its domestic business. Though the company hasn’t seen growth in its international segment, Indoco management says the firm is on track to perform better in the next quarter.
India’s Indoco has reported double-digit sales growth, as well as a jump in operating profit and EBITDA for its financial second quarter ended 30 September 2021. The company has seen consistent growth on the back on domestic and international launches.
Indoco has seen double-digit growth in domestic and international markets in the first quarter of financial year 2022. Headquartered in Mumbai, Indoco has reported overall growth of almost 43% and an increase of 124.6% in its operating profit in Q1 FY22.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- NasVax Ltd.
- Therapix Biosciences Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.